Companies › BeyondBio
1 active drug program in 3 registered trials: 3 Phase 1; Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BEY1107 | – | Phase 1 | Glioblastoma Multiforme; Locally Advanced or Metastatic Pancreatic Cancer; Metastatic Colorectal Cancer | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05769660 | BEY1107 | Phase 1 | Glioblastoma Multiforme | Oncology | Nov 2026 |
| NCT03579836 | BEY1107 | Phase 1 | Locally Advanced or Metastatic Pancreatic Cancer | Oncology | Nov 2026 |
| NCT05093907 | BEY1107 | Phase 1 | Metastatic Colorectal Cancer | Oncology | Nov 2026 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.